RG 201

Drug Profile

RG 201

Alternative Names: RG 001

Latest Information Update: 18 Jul 1996

Price : $50

At a glance

  • Originator University of North Carolina
  • Developer Pharm-Eco Laboratories; Questcor Pharmaceuticals; University of North Carolina
  • Class Antifungals; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Giardiasis; Pneumocystis pneumonia

Most Recent Events

  • 18 Jul 1996 Discontinued-I for Pneumocystis pneumonia in USA (Unknown route)
  • 18 Jul 1996 Discontinued-Preclinical for Giardiasis in USA (Unknown route)
  • 31 Oct 1995 Preclinical development for Giardiasis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top